ClinicalTrials.gg
CompletedNCT02889848Updated Jul 10, 2019

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

A Phase 1 interventional study of Saline and EN3835 in Fibroids, Uterine and Leiomyoma, sponsored by Advance Biofactures Corporation. Completed at 1 site in United States. Open to female participants aged 35 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-07-10.

Sponsored by Advance Biofactures Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
35 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 156 studies in Leiomyoma with a site in United States — 20 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.

Enrollment
102nd of 121
15 · median 57
Started
2016
with 9 others
Phase 1
13 of 156
1 open now
Registered
88th of 156
by date

Among the 156 studies in Leiomyoma with a site in United States, this one is the 102nd largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2016, is one of 13 in phase 1, and was the 88th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 35 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Leiomyoma with a site in United States, or all of them as a file.
02

Study summary

This pilot study evaluates the safety and tolerability of a single injection of collagenase enzyme directly into a uterine fibroid in subjects already selected for hysterectomy or myomectomy.

Fibroids contain excessive amounts of collagen and it is possible that digestion of collagen may be beneficial in reducing pain and bleeding associated with fibroids.

Three subjects will be injected with saline only to evaluate the safety and effectiveness of the injection method. Additional subjects will then be injected with increasing doses of study drug.

Read the detailed description

Collagenase enzyme breaks down collagen and has shown efficacy in clinical trials for a number of diseases for which there is an accumulation of collagen.

It is possible that lysis of collagen may reduce the collagen content of fibroids thus decreasing the size of fibroids, and possibly reducing the stiffness of fibroids. This may result in reducing the symptoms of pain and bleeding associated with fibroids.

In this study three subjects will be injected with saline only followed immediately by hysterectomy in order to evaluate the safety and effectiveness of the injection method.

Twelve subjects will receive a single injection of study drug as follows: three subjects will receive a set dose of collagenase enzyme followed by hysterectomy or myomectomy 24-96 hours later (Group 1) to evaluate safety of the injection of study drug. Nine subjects will then receive increasing doses of collagenase enzyme followed by hysterectomy or myomectomy 60-90 days later (Group 2).

03

Conditions studied

  • Fibroids, Uterine
  • Leiomyoma

Browse trials for

04

Who can participate

Ages eligible
35 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parous and non-parous women who have completed child-bearing (age criteria of > 35 years-old, and \<50 years-old)
  • Currently practicing or willing to practice throughout the duration of the study
  • Women with at least one or two fibroids greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 1, and at least one fibroid greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 2
  • Fibroids will be intramural fibroids which will be surrounded by a layer of myometrium. Fibroids must be well visualized on ultrasound examination and provide a clear path for injection
  • Women who were planning to undergo abdominal hysterectomy or myomectomy for treatment of symptomatic fibroids. Subjects must be willing to defer the operation until 24-96 hours after study treatment for Group 1 and for 60-90 days after study treatment for Group 2. The patients will understand that they may choose to have surgery or any other non-study treatment at any time after enrollment and end study participation
  • "Typical" large fibroids visualized as hypo-intense on a T2-weighted MRI scan

Exclusion criteria

Exclusion Criteria:

  • Inability to understand study procedures or to comply with study visits and requirements
  • > 40kg/m2
  • History of allergic reaction to study medication (Collagenase Clostridium Histolyticum) or any components of the study drug
  • Inability to undergo hysterectomy or myomectomy
  • Inability to tolerate MRI and transvaginal ultrasound procedures (i.e. presence of an intra-uterine device (IUD), pacemakers, aneurismal clips or other metallic devices that are not compatible with magnetic resonance imaging). However women with IUD's compatible with MRI are eligible for the study
  • Medical problems including: genetic diseases that cause fibroids, history of thromboembolic (blood clot) events or need for anticoagulation (Coumadin, Heparin, etc.) Subjects taking or planning to take anti-coagulant medication (except for ≤ 150 mg aspirin daily) within 7 days administration study drug and within 7 days before and after hysterectomy
  • A history of cancer within the past 5 years
  • Abnormal liver function tests (typically, will be >20% elevation). Mild elevations will be at the discretion of the investigators, but undiagnosed liver conditions will represent an exclusion criterion
  • Pregnancy or lactation. Pregnancy will be evaluated by urine test every 30 days if necessary. Patients will be asked to use non-hormonal methods while in this study
  • Severe anemia (hematocrit \<30). Mild anemia is common in women with fibroids
  • Recent rapid growth of fibroids (i.e. doubling in size within one-six months period)
  • Any use of agents like Imidazoles, due to possible interference with metabolism
  • Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass)
  • Fibroids that are visualized on T2 and T1 weighted MRI as hyperdense or show cystic degeneration
  • Inability to undergo injection of fibroid with study drug for any reason, anatomic or other
  • Has a known systemic allergy to collagenase or any other of EN3835 or any other procedural medication
  • Has, at any time, received collagenase as a treatment
  • Is planning to be treated with commercial XIAFLEX at any time during the study
  • Type 0 submucosal fibroids, submucosal fibroids with significant protrusion/ pedunculation and subserosal fibroids are not appropriate candidates for the injections
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Sham comparator
    Saline only

    Injection of saline to assess the injection procedure

    Other: Saline

  • Experimental
    1.16 mg EN3835

    Injection of maximum marketed dose of EN3835 regardless of fibroid size

    Drug: EN3835

  • Experimental
    Dose 1

    Injection of 0.05 mg EN3835 per cm3 fibroid

    Drug: EN3835

  • Experimental
    Dose 2

    Injection of 0.1 mg EN3835 per cm3 fibroid

    Drug: EN3835

  • Experimental
    Dose 3

    Injection of 0.2 mg EN3835 per cm3 fibroid

    Drug: EN3835

Interventions

  • OtherSaline

    Saline injection

  • DrugEN3835

    Comparison of maximum marketed dose and multiple doses EN3835

    Also known as: Collagenase clostridium histolyticum

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events following a single injection of EN3835 into a fibroid

    Assessed by number of subjects with uterine injury or peritoneal irritation determined post hysterectomy

    Time frame: Through hysterectomy or myomectomy (average = 60-90 days post injection)

Secondary outcomes

  1. Change in symptoms of pain and bleeding and quality of life

    Determined by standardized questionnaires for menstrual distress, quality of life and sexual activity; McGill Pain Questionnaire

    Time frame: Throughout the study prior to hysterectomy or myomectomy(avg 60-90 days post injection study drug)

  2. Reduction in size of treated fibroids- Group 2

    Size of fibroid to be determined post hysterectomy or myomectomy

    Time frame: 60-90 days post injection study drug

  3. Increased rate of apoptosis of treated fibroids -Group 2

    Specimens to be taken post hysterectomy or myomectomy and evaluated by TUNEL staining

    Time frame: 60-90 days post injection study drug

  4. Reduction in collagen content of treated fibroids-Group 2

    Specimens to be taken post hysterectomy or myomectomy and by tested histology stains

    Time frame: 60-90 days post injection study drug

  5. Reduction in stiffness of treated fibroid-Group 2

    Specimens to be taken post hysterectomy or myomectomy and tested via rheometry

    Time frame: 60-90 days post injection study drug

07

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
08

References and documents

Publications

  • Islam MS, Afrin S, Singh B, Jayes FL, Brennan JT, Borahay MA, Leppert PC, Segars JH. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. Clin Transl Med. 2021 Jul;11(7):e475. doi: 10.1002/ctm2.475. PubMed 34323413 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Oct 2018, 23 months.

Of 13 phase 1 interventional studies under Leiomyoma, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 41. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2016
First posted
Sep 7, 2016
StartActual
Oct 27, 2016
Primary completionActual
Oct 5, 2018
CompletionActual
Nov 15, 2018
Last update
Jul 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02889848
Lead sponsor
Advance Biofactures Corporation
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Oct 27, 2016
Primary completion
Oct 5, 2018
Completion
Nov 15, 2018
Last update
Jul 10, 2019

Study contacts

James Segars, M.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion